Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate
the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome
injection in patients with platinum-resistant relapsed epithelial ovarian cancer.